TY  -  
T1  - Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria : An Open-Label, Phase 1, Dose-Adjustment Trial 
SN  -  /  
UR  - http://hdl.handle.net/10138/235283 
T3  -  
A1  - Chen, Ingrid; Diawara, Halimatou; Mahamar, Almahamoudou; Sanogo, Koualy; Keita, Sekouba; Kone, Daouda; Diarra, Kalifa; Djimde, Mousse; Keita, Mohamed; Brown, Joelle; Roh, Michelle E.; Hwang, Jimee; Pett, Helmi; Murphy, Maxwell; Niemi, Mikko; Greenhouse, Bryan; Bousema, Teun; Gosling, Roly; Dicko, Alassane 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - Methods: We conducted an open-label, nonrandomized, dose-adjustment trial of the safety of 3 single doses of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient adult males in Mali, followed by an assessment of safety in G6PD-deficient boys aged 11–17 years and those aged 5–10 years, including G6PD-normal control groups. The primary outcome was the greatest within-person percentage drop in hemoglobin concentration within 10 days after treatment. Results: Fifty-one participants were ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Primaquine; Plasmodium falciparum; malaria; transmission; G6PD deficiency; drug safety; hemolysis; mass drug administration; PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL; DEFICIENCY; TRANSMISSION; HEMOLYSIS; EFFICACY; AFRICA; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -